Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
Study sponsor: MBX Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-05-23Actual
Enrollment · participants64Actual
Source updated2026-03-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.